Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Systematic Review Article

Effect of Statins on the Blood Lipid Profile in Patients with Different Cardiovascular Diseases: A Systematic Review with Meta-analysis of Randomized Clinical Trials

Author(s): Saeed Aslani, Bahman Razi*, Danyal Imani, Keyhan Mohammadi, Tannaz Jamialahmadi, Željko Reiner and Amirhossein Sahebkar*

Volume 30, Issue 32, 2023

Published on: 27 December, 2022

Page: [3702 - 3724] Pages: 23

DOI: 10.2174/0929867330666221129094921

Price: $65

Abstract

Background: Statins are the main lipid-lowering drugs and are used in the prevention of cardiovascular diseases (CVDs). Since the results have been, to some extent, inconsistent in the clinical trials concerning different types of CVDs, a systematic review and meta-analysis was performed to prove the effect of statins on decreasing elevated levels of total cholesterol, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in patients with CVDs.

Methods: Literature search was performed on major electronic databases (MEDLINE/ PubMed, Scopus, and ISI Web of Science) from inception up to July 2021 to find randomized controlled trials (RCTs) evaluating the effect of different statins on different types of CVDs. The effect size was determined using weighted mean difference (WMD) and corresponding 95% confidence interval (CI).

Results: Statin therapy significantly decreased levels of total cholesterol (WMD = -33.37 mg/dl, 95% CI: -45.98 to -20.76, P<0.001), LDL-C (WMD = -29.42 mg/dl, 95% CI: -36.81 to -22.03, P<0.001), and TG (WMD = -15.19 mg/dl, 95% CI = -26.41 to -3.97, P<0.001), and increased levels of HDL-C (WMD = 1.55 mg/dl, 95% CI: 0.20, to 2.90, P=0.02) in patients with different CVDs.

Conclusion: Statin therapy was found effective in lowering levels of total cholesterol, LDL-C, and TG, and increasing levels of HDL-C in patients with different CVDs.

Keywords: Statins, cardiovascular diseases, cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol.

« Previous
[1]
Parsamanesh, N.; Karami-Zarandi, M.; Banach, M.; Penson, P.E.; Sahebkar, A. Effects of statins on myocarditis: A review of underlying molecular mechanisms. Prog. Cardiovasc. Dis., 2021, 67, 53-64.
[http://dx.doi.org/10.1016/j.pcad.2021.02.008] [PMID: 33621589]
[2]
Rauch, U.; Osende, J.I.; Chesebro, J.H.; Fuster, V.; Vorchheimer, D.A.; Harris, K.; Harris, P.; Sandler, D.A.; Fallon, J.T.; Jayaraman, S.; Badimon, J.J. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis, 2000, 153(1), 181-189.
[http://dx.doi.org/10.1016/S0021-9150(00)00397-X] [PMID: 11058714]
[3]
Reiner, Ž.; De Backer, G.; Fras, Z.; Kotseva, K.; Tokgözoglu, L.; Wood, D.; De Bacquer, D. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey. Atherosclerosis, 2016, 246, 243-250.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.01.018] [PMID: 26812002]
[4]
Reiner, Ž.; De Bacquer, D.; Kotseva, K.; Prugger, C.; De Backer, G.; Wood, D. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. Atherosclerosis, 2013, 231(2), 300-307.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.09.020] [PMID: 24267243]
[5]
Reiner, Ž. Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol., 2013, 10(8), 453-464.
[http://dx.doi.org/10.1038/nrcardio.2013.80] [PMID: 23736519]
[6]
Hegele, R.A.; Tsimikas, S. Lipid-lowering agents. Circ. Res., 2019, 124(3), 386-404.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.313171] [PMID: 30702996]
[7]
Sahebkar, A.; Watts, G.F. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect? Cardiovasc. Drugs Ther., 2013, 27(6), 559-567.
[http://dx.doi.org/10.1007/s10557-013-6479-4] [PMID: 23913122]
[8]
Sahebkar, A.; Watts, G.F. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther., 2013, 35(8), 1082-1098.
[http://dx.doi.org/10.1016/j.clinthera.2013.06.019] [PMID: 23932550]
[9]
Sahebkar, A.; Chew, G.T.; Watts, G.F. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog. Lipid Res., 2014, 56(1), 47-66.
[http://dx.doi.org/10.1016/j.plipres.2014.07.002] [PMID: 25083925]
[10]
Sweetman, S.C. Martindale: The complete drug reference; Pharmaceutical Press: London, UK, 2009.
[11]
Katsiki, N.; Reiner, Ž.; Tedeschi Reiner, E.; Al-Rasadi, K.; Pirro, M.; Mikhailidis, D.P.; Sahebkar, A. Improvement of endothelial function by pitavastatin: A meta-analysis. Expert Opin. Pharmacother., 2018, 19(3), 279-286.
[http://dx.doi.org/10.1080/14656566.2018.1428560] [PMID: 29334477]
[12]
Bahrami, A.; Bo, S.; Jamialahmadi, T.; Sahebkar, A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res. Rev., 2020, 58, 101024.
[http://dx.doi.org/10.1016/j.arr.2020.101024] [PMID: 32006687]
[13]
Bahrami, A.; Parsamanesh, N.; Atkin, S.L.; Banach, M.; Sahebkar, A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol. Res., 2018, 135, 230-238.
[http://dx.doi.org/10.1016/j.phrs.2018.08.014] [PMID: 30120976]
[14]
Khalifeh, M.; Penson, P.; Banach, M.; Sahebkar, A. Statins as anti-pyroptotic agents. Arch. Med. Sci., 2021, 17(5), 1414-1417.
[http://dx.doi.org/10.5114/aoms/141155] [PMID: 34522271]
[15]
Skowerski, T.; Skowerski, M.; Grzywocz, P.; Kułach, A.; Gąsior, Z. Acute pericarditis in a young patient with IgG immunodeficiency. Arch. Med. Sci., 2020, 16(6), 1461-1463.
[http://dx.doi.org/10.5114/aoms.2020.100307] [PMID: 33224349]
[16]
Sahebkar, A.; Serban, C.; Mikhailidis, D. P.; Undas, A.; Lip, G. Y.; Muntner, P.; Bittner, V.; Ray, K. K.; Watts, G. F.; Hovingh, G. K.; Rysz, J.; Kastelein, J. J.; Banach, M. & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemo, 2015, 114(3), 546-557.
[http://dx.doi.org/10.1160/TH14-11-0937]
[17]
Vahedian-Azimi, A.; Mohammadi, S.; Beni, F.; Banach, M.; Guest, P.; Jamialahmadi, T.; Sahebkar, A. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: A systematic review and meta-analysis. Arch. Med. Sci., 2021, 17(3), 579-595.
[http://dx.doi.org/10.5114/aoms/132950] [PMID: 34025827]
[18]
INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: Randomized controlled trial. BMJ, 2022, 376, e068407.
[PMID: 34996756]
[19]
Koushki, K.; Shahbaz, S.K.; Mashayekhi, K.; Sadeghi, M.; Zayeri, Z.D.; Taba, M.Y.; Banach, M.; Al-Rasadi, K.; Johnston, T.P.; Sahebkar, A. Anti-inflammatory Action of Statins in Cardiovascular Disease: The Role of Inflammasome and Toll-Like Receptor Pathways. Clin. Rev. Allergy Immunol., 2021, 60(2), 175-199.
[http://dx.doi.org/10.1007/s12016-020-08791-9] [PMID: 32378144]
[20]
Parizadeh, S.M.R.; Azarpazhooh, M.R.; Moohebati, M.; Nematy, M.; Ghayour-Mobarhan, M.; Tavallaie, S.; Rahsepar, A.A.; Amini, M.; Sahebkar, A.; Mohammadi, M.; Ferns, G.A.A. Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial. Lipids, 2011, 46(4), 333-340.
[http://dx.doi.org/10.1007/s11745-010-3517-x] [PMID: 21207250]
[21]
Dehnavi, S.; Kiani, A.; Sadeghi, M.; Biregani, A.F.; Banach, M.; Atkin, S.L.; Jamialahmadi, T.; Sahebkar, A. Targeting AMPK by statins: A potential therapeutic approach. Drugs, 2021, 81(8), 923-933.
[http://dx.doi.org/10.1007/s40265-021-01510-4] [PMID: 33939118]
[22]
a) Kouhpeikar, H.; Delbari, Z.; Sathyapalan, T.; Simental-Mendía, L.E.; Jamialahmadi, T.; Sahebkar, A. The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review. Curr. Atheroscler. Rep., 2020, 22(5), 19.
[http://dx.doi.org/10.1007/s11883-020-00837-9] [PMID: 32458165];
b) Serban, C.; Sahebkar, A.; Ursoniu, S.; Mikhailidis, D. P.; Rizzo, M.; Lip, G. Y.; Kees Hovingh, G.; Kastelein, J. J.; Kalinowski, L.; Rysz, J.; & Banach, M. (2015). A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Scientific reports 5, 9902.
[http://dx.doi.org/10.1038/srep09902];
c) Sahebkar, A.; Kotani, K.; Serban, C.; Ursoniu, S.; Mikhailidis, D. P.; Jones, S. R.; Ray, K. K.; Blaha, M. J.; Rysz, J.; Toth, P. P.; Muntner, P.; Lip, G. Y.; Banach, M. & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2015). Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. Atherosclerosis, 241(2), 433-442.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.022]
[23]
Andrews, T.C.; Ballantyne, C.M.; Hsia, J.A.; Kramer, J.H. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am. J. Med., 2001, 111(3), 185-191.
[http://dx.doi.org/10.1016/S0002-9343(01)00799-9] [PMID: 11530028]
[24]
Ahnadi, C.E.; Berthezène, F.; Ponsin, G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis, 1993, 99(2), 219-228.
[http://dx.doi.org/10.1016/0021-9150(93)90024-O] [PMID: 8503950]
[25]
Zhao, S.P.; Smelt, A.H.; Van den Maagdenberg, A.M.; Van Tol, A.; Vroom, T.F.; Gevers Leuven, J.A.; Frants, R.R.; Havekes, L.M.; Van der Laarse, A.; Van ’t Hooft, F.M. Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin. Arterioscler. Thromb., 1994, 14(11), 1705-1716.
[http://dx.doi.org/10.1161/01.ATV.14.11.1705] [PMID: 7947593]
[26]
Napoli, C.; Leccese, M.; Palumbo, G.; de Nigris, F.; Chiariello, P.; Zuliani, P.; Somma, P.; Loreto, M.D.; Matteis, C.D.; Cacciatore, F.; Abete, P.; Liguori, A.; Chiariello, M.; DʼArmiento, F.P. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron. Artery Dis., 1998, 9(5), 257-264.
[http://dx.doi.org/10.1097/00019501-199809050-00003] [PMID: 9710685]
[27]
McTaggart, F.; Jones, P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc. Drugs Ther., 2008, 22(4), 321-338.
[http://dx.doi.org/10.1007/s10557-008-6113-z] [PMID: 18553127]
[28]
Yun, K.H.; Jeong, M.H.; Oh, S.K.; Rhee, S.J.; Park, E.M.; Lee, E.M.; Yoo, N.J.; Kim, N.H.; Ahn, Y.K.; Jeong, J.W. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int. J. Cardiol., 2009, 137(3), 246-251.
[http://dx.doi.org/10.1016/j.ijcard.2008.06.055] [PMID: 18706705]
[29]
Yang, J; Li, XP; Zhao, SP; Li, J; Li, JD; Xie, XM The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clin. Chim. Acta., 2006, 368(1-2), 183-7.
[http://dx.doi.org/10.1016/j.cca.2005.12.029]
[30]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021, 372, n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[31]
Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials, 1996, 17(1), 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[32]
Ryan, R. How to GRADE the quality of the evidence. Hill SJCc, group c., 2016, 3
[33]
Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 2005, 5(1), 13.
[http://dx.doi.org/10.1186/1471-2288-5-13] [PMID: 15840177]
[34]
Altman, D.G.; Bland, J.M. Standard deviations and standard errors. BMJ, 2005, 331(7521), 903.
[http://dx.doi.org/10.1136/bmj.331.7521.903] [PMID: 16223828]
[35]
DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials, 1986, 7(3), 177-188.
[http://dx.doi.org/10.1016/0197-2456(86)90046-2] [PMID: 3802833]
[36]
Higgins, J.P.T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, 21(11), 1539-1558.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[37]
Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; Goldberg, R.; Heidenreich, P.A.; Hlatky, M.A.; Jones, D.W.; Lloyd-Jones, D.; Lopez-Pajares, N.; Ndumele, C.E.; Orringer, C.E.; Peralta, C.A.; Saseen, J.J.; Smith, S.C., Jr; Sperling, L.; Virani, S.S.; Yeboah, J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation, 2019, 139(25), e1082-e1143.
[PMID: 30586774]
[38]
Climent, E.; Benaiges, D.; Pedro-Botet, J. Hydrophilic or lipophilic statins? Front. Cardiovasc. Med., 2021, 8, 687585.
[http://dx.doi.org/10.3389/fcvm.2021.687585] [PMID: 34095267]
[39]
Begg, C.B.; Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50(4), 1088-1101.
[http://dx.doi.org/10.2307/2533446] [PMID: 7786990]
[40]
Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109), 629-634.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[41]
Qiao, L.; Wang, S.; Jia, Q.; Bian, J.; Fan, Y.; Xu, X. Clinical efficacy and safety of statin treatment after carotid artery stenting. Artif. Cells Nanomed. Biotechnol., 2019, 47(1), 3110-3115.
[http://dx.doi.org/10.1080/21691401.2019.1645149] [PMID: 31352800]
[42]
Guo, S.; Wang, R.; Yang, Z.; Li, K.; Wang, Q. Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaques. Exp. Ther. Med., 2012, 4(6), 1069-1074.
[http://dx.doi.org/10.3892/etm.2012.722] [PMID: 23226776]
[43]
Dohi, T.; Miyauchi, K.; Okazaki, S.; Yokoyama, T.; Yanagisawa, N.; Tamura, H.; Kojima, T.; Yokoyama, K.; Kurata, T.; Daida, H. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study. Atherosclerosis, 2010, 210(2), 497-502.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.12.001] [PMID: 20036363]
[44]
Xu, Y.; Hu, H.; Li, Y.; Cen, R.; Yao, C.; Ma, W.; Huang, M.; Yin, Y.; Gao, H.; Liu, Y.; Endler, A. Effects of huoxin formula on the arterial functions of patients with coronary heart disease. Pharm. Biol., 2019, 57(1), 13-20.
[http://dx.doi.org/10.1080/13880209.2018.1561726] [PMID: 31199705]
[45]
Chan, K.C.; Chou, H.H.; Huang, C.N.; Chou, M.C. Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: Impact on plasma adiponectin level. Clin. Cardiol., 2008, 31(6), 253-258.
[http://dx.doi.org/10.1002/clc.20181] [PMID: 18543304]
[46]
Karaca, I.; ilkay, E.; Akbulut, M.; Yavuzkır, M.; Pekdemir, M.; Akbulut, H.; Arslan, N. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Curr. Med. Res. Opin., 2003, 19(3), 187-191.
[http://dx.doi.org/10.1185/030079903125001686] [PMID: 12803732]
[47]
Strazhesko, I.D.; Tkacheva, O.N.; Akasheva, D.U.; Dudinskaya, E.N.; Plokhova, E.V.; Pykhtina, V.S.; Kruglikova, A.S.; Kokshagina, N.V.; Sharashkina, N.V.; Agaltsov, M.V.; Kashtanova, D.A.; Vygodin, V.A.; Ozerova, I.N.; Skvortsov, D.A.; Vasilkova, D.; Boytsov, S.A. Atorvastatin therapy modulates telomerase activity in patients free of atherosclerotic cardiovascular diseases. Front. Pharmacol., 2016, 7, 347.
[http://dx.doi.org/10.3389/fphar.2016.00347] [PMID: 27746733]
[48]
Link, A.; Ayadhi, T.; Böhm, M.; Nickenig, G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur. Heart J., 2006, 27(24), 2945-2955.
[http://dx.doi.org/10.1093/eurheartj/ehl277] [PMID: 17012299]
[49]
Lewandowski, M.; Kornacewicz-Jach, Z.; Millo, B.; Zielonka, J.; Czechowska, M.; Kaliszczak, R.; Płońska, E.; Goracy, J.; Kaźmierczak, J.; Naruszewicz, M. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol. J., 2008, 15(4), 357-364.
[PMID: 18698545]
[50]
Cleland, J.G.F.; McMurray, J.J.V.; Kjekshus, J.; Cornel, J.H.; Dunselman, P.; Fonseca, C.; Hjalmarson, Å.; Korewicki, J.; Lindberg, M.; Ranjith, N.; van Veldhuisen, D.J.; Waagstein, F.; Wedel, H.; Wikstrand, J. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J. Am. Coll. Cardiol., 2009, 54(20), 1850-1859.
[http://dx.doi.org/10.1016/j.jacc.2009.06.041] [PMID: 19892235]
[51]
Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C.A.; Dimopoulos, M.A.; Stefanadis, C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study. Atherosclerosis, 2010, 210(1), 194-198.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.10.046] [PMID: 19962701]
[52]
Abulhul, E.; McDonald, K.; Martos, R.; Phelan, D.; Spiers, J.P.; Hennessy, M.; Baugh, J.; Watson, C.; O’Loughlin, C.; Ledwidge, M. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. Clin. Ther., 2012, 34(1), 91-100.
[http://dx.doi.org/10.1016/j.clinthera.2011.11.002] [PMID: 22154198]
[53]
Macin, S.M.; Perna, E.R.; Farías, E.F.; Franciosi, V.; Cialzeta, J.R.; Brizuela, M.; Medina, F.; Tajer, C.; Doval, H.; Badaracco, R. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study. Am. Heart J., 2005, 149(3), 451-457.
[http://dx.doi.org/10.1016/j.ahj.2004.07.041] [PMID: 15864233]
[54]
Correia, L.C.L.; Spósito, A.C.; Lima, J.C.; Magalhães, L.P.; Passos, L.C.S.; Rocha, M.S.; D’Oliveira, A., Jr; Esteves, J.P. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non–Q-wave acute myocardial infarction. Am. J. Cardiol., 2003, 92(3), 298-301.
[http://dx.doi.org/10.1016/S0002-9149(03)00630-1] [PMID: 12888137]
[55]
Sola, S.; Mir, M.Q.S.; Khan, B.V.; Lerakis, S.; Tandon, N. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J. Am. Coll. Cardiol., 2006, 47(2), 332-337.
[http://dx.doi.org/10.1016/j.jacc.2005.06.088] [PMID: 16412856]
[56]
Suzuki, T.; Nozawa, T.; Sobajima, M.; Igarashi, N.; Matsuki, A.; Fujii, N.; Inoue, H. Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease. Int. Heart J., 2008, 49(4), 423-433.
[http://dx.doi.org/10.1536/ihj.49.423] [PMID: 18753726]
[57]
Nakagomi, A.; Seino, Y.; Kohashi, K.; Kosugi, M.; Endoh, Y.; Kusama, Y.; Atarashi, H.; Mizuno, K. Effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia. Circ. J., 2012, 76(9), 2130-2138.
[http://dx.doi.org/10.1253/circj.CJ-11-1123] [PMID: 22785006]
[58]
Jiao, Y.; Hu, F.; Zhang, Z.; Gong, K.; Sun, X.; Li, A.; Liu, N. Efficacy and safety of loading-dose rosuvastatin therapy in elderly patients with acute coronary syndromes undergoing elective percutaneous coronary intervention. Clin. Drug Investig., 2015, 35(12), 777-784.
[http://dx.doi.org/10.1007/s40261-015-0335-1] [PMID: 26387028]
[59]
Marschang, P.; Friedrich, G.J.; Ditlbacher, H.; Stoeger, A.; Nedden, D.; Kirchmair, R.; Dienstl, A.; Pachinger, O.; Patsch, J.R. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int. J. Cardiol., 2006, 106(2), 183-190.
[http://dx.doi.org/10.1016/j.ijcard.2005.01.042] [PMID: 16321690]
[60]
McMurray, J.J.V.; Kjekshus, J.; Gullestad, L.; Dunselman, P.; Hjalmarson, Å.; Wedel, H.; Lindberg, M.; Waagstein, F.; Grande, P.; Hradec, J.; Kamenský, G.; Korewicki, J.; Kuusi, T.; Mach, F.; Ranjith, N.; Wikstrand, J. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation, 2009, 120(22), 2188-2196.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.849117] [PMID: 19917888]
[61]
Zhang, X.; Xing, L.; Jia, X.; Pang, X.; Xiang, Q.; Zhao, X.; Ma, L.; Liu, Z.; Hu, K.; Wang, Z.; Cui, Y. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: Systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc. Ther., 2020, 2020, 1-21.
[http://dx.doi.org/10.1155/2020/3987065] [PMID: 32411300]
[62]
Zhu, Y.; Hu, H.; Yang, J.; Yao, Q.; Xu, H.; Yu, Y.; Liu, T.; Lin, S. The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis. Bosn. J. Basic Med. Sci., 2020, 20(2), 169-182.
[PMID: 31668143]
[63]
Milionis, H.; Ntaios, G.; Korompoki, E.; Vemmos, K.; Michel, P. Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview. Int. J. Stroke, 2020, 15(4), 377-384.
[http://dx.doi.org/10.1177/1747493019873594] [PMID: 31496436]
[64]
Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L.E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E.H.; Keech, A.; Simes, J.; Collins, R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet, 2010, 376(9753), 1670-1681.
[http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 21067804]
[65]
Preiss, D.; Campbell, R.T.; Murray, H.M.; Ford, I.; Packard, C.J.; Sattar, N. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J., 2015, 36(24), 1536-46.
[66]
Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M.R.; Tokgozoglu, L.; Wiklund, O.; Mueller, C.; Drexel, H.; Aboyans, V.; Corsini, A.; Doehner, W.; Farnier, M.; Gigante, B.; Kayikcioglu, M.; Krstacic, G.; Lambrinou, E.; Lewis, B.S.; Masip, J.; Moulin, P.; Petersen, S.; Petronio, A.S.; Piepoli, M.F.; Pintó, X.; Räber, L.; Ray, K.K.; Reiner, Ž.; Riesen, W.F.; Roffi, M.; Schmid, J-P.; Shlyakhto, E.; Simpson, I.A.; Stroes, E.; Sudano, I.; Tselepis, A.D.; Viigimaa, M.; Vindis, C.; Vonbank, A.; Vrablik, M.; Vrsalovic, M.; Zamorano, J.L.; Collet, J-P.; Koskinas, K.C.; Casula, M.; Badimon, L.; John Chapman, M.; De Backer, G.G.; Delgado, V.; Ference, B.A.; Graham, I.M.; Halliday, A.; Landmesser, U.; Mihaylova, B.; Pedersen, T.R.; Riccardi, G.; Richter, D.J.; Sabatine, M.S.; Taskinen, M-R.; Tokgozoglu, L.; Wiklund, O.; Windecker, S.; Aboyans, V.; Baigent, C.; Collet, J-P.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gale, C.P.; Grobbee, D.; Halvorsen, S.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Landmesser, U.; Leclercq, C.; Lettino, M.; Lewis, B.S.; Merkely, B.; Mueller, C.; Petersen, S.; Petronio, A.S.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Touyz, R.M.; Nibouche, D.; Zelveian, P.H.; Siostrzonek, P.; Najafov, R.; van de Borne, P.; Pojskic, B.; Postadzhiyan, A.; Kypris, L.; Špinar, J.; Larsen, M.L.; Eldin, H.S.; Viigimaa, M.; Strandberg, T.E.; Ferrières, J.; Agladze, R.; Laufs, U.; Rallidis, L.; Bajnok, L.; Gudjónsson, T.; Maher, V.; Henkin, Y.; Gulizia, M.M.; Mussagaliyeva, A.; Bajraktari, G.; Kerimkulova, A.; Latkovskis, G.; Hamoui, O.; Slapikas, R.; Visser, L.; Dingli, P.; Ivanov, V.; Boskovic, A.; Nazzi, M.; Visseren, F.; Mitevska, I.; Retterstøl, K.; Jankowski, P.; Fontes-Carvalho, R.; Gaita, D.; Ezhov, M.; Foscoli, M.; Giga, V.; Pella, D.; Fras, Z.; de Isla, L.P.; Hagström, E.; Lehmann, R.; Abid, L.; Ozdogan, O.; Mitchenko, O.; Patel, R.S. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020, 41(1), 111-188.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[67]
Soran, H.; Dent, R.; Durrington, P. Evidence-based goals in LDL-C reduction. Clin. Res. Cardiol., 2017, 106(4), 237-248.
[http://dx.doi.org/10.1007/s00392-016-1069-7] [PMID: 28124099]

Rights & Permissions Print Cite
Article Metrics
62
2
Wayfinder Image
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy